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ABSTRACT. Hepcidin prevents absorption of iron from the intestine and inhibits release of iron 
from macrophages and hepatocytes. For this reason, it seems that high levels of hepcidin are a 
predisposing factor for anemia in chronic inflammatory conditions such as chronic kidney disease 
and dialysis patients. This study was designed to determine the role of changes in the level of 
serum hepcidin in the management of hemodialysis patients. This study included 44 dialysis 
patients and 44 controls. The hepcidin and pro-hepcidin levels were measured by the enzyme-
linked immunosorbent assay method. The serum ferritin level was measured by the chemi­
luminescence method. The mean hepcidin level was 999.3 ± 996.7 ng/mL in the case group and 
770.4 ± 815.9 ng/mL in the control group (P = 0.25). The mean pro-hepcidin level was, respec­
tively, 186.1 ± 220.3 pg/mL and 150.87 ± 207.7 pg/mL, in the case group and control groups (P = 
0.45). The mean (standard deviation) ferritin level was 816.4 ± 379.4 ng/mL in the case group and 
193 ± 171.8 ng/mL in the control group (P <0.001). In the case group, the correlation between 
serum ferritin and hepcidin was not significant (r = 0.6, P = 0.08). Also, there was no significant 
correlation between serum ferritin and pro-hepcidin levels (r = 0.6, P = 0.08). A positive corre­
lation was seen between pro-hepcidin and hepcidin levels (r = 0.92, P <0.01). In this study, the 
results showed that the serum hepcidin levels are high in dialysis patients and that there was no 
correlation with the serum ferritin levels. 
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anemia of chronic diseases that is often of the 
normochromic normocytic type. Anemia of 
chronic diseases is seen in many diseases 
associated with inflammation, such as cancer, 
chronic infections and autoimmune diseases.2 
Anemia is a major factor in many of the symp­
toms associated with decreased renal function. 
These complications cause a significant in­
crease in mortality due to cardiovascular di­
sease in dialysis patients.3 The kidneys are the 
primary site for the synthesis of erythropoietin 
(EPO) in adults. Interleukin-6 is the most im­
portant cytokine involved in the production of 
hepcidin and the inflammatory condition axis 
of hepcidin–interleukin (IL)-6 is responsible 
for iron deficiency during inflammation.4,5
  Hepcidin is a low molecular weight protein 
that has recently been discovered and plays an 
important role in iron metabolism. It is a 
regulator of renal iron homeostasis.6 Pre-pro­
hepcidin, with 84 amino acids, is produced in 
the hepatocytes and is then broken down to 60 
amino acid pro-hepcidin that appears in the 
plasma.7 Hepcidin prevents the release of iron 
from the macrophages and decreases iron ab­
sorption in the intestine.8 Various physiolo­
gical and pathological conditions are effective 
in the synthesis of hepcidin. On the other 
hand, synthesis of hepcidin increases in infec­
tions and inflammatory processes.9
  Hepcidin is considered as one of the acute 
phase proteins. It is believed that this effect 
can lead to anemia of chronic disease, which is 
caused by a decrease of circulating iron avai­
lable for erythropoiesis, despite normal iron 
stores.10 The hepcidin level increases in pa­
tients with CRF and hemodialysis (HD) pa­
tients.11,12 Hepcidin is cleared only in some 
patients during dialysis. Exactly why this hap­
pens is not clear yet, but it may be due to 
differences in the membranes of various dia­
lyzers, state of kidney function or induction of 
hepcidin during the process of HD.6 Hepcidin 
may be associated with resistance to factors 
triggering the production of EPO and an 
imbalance in iron metabolism in CRF patients. 
In addition, hepcidin can also be discussed as a 
therapeutic agent as decreasing the levels of 
hepcidin can lead to improved iron uptake 
from the intestine and macrophages; thus, anti­
hepcidin therapy can be a substitute for intra­
venous iron therapy.13 The aim of this study 
was to evaluate the level of pro-hepcidin and 
hepcidin in patients with CRF on HD. 
Materials and Methods
  In this study, 44 HD patients and 44 healthy 
controls were sampled. Before dialysis, 6 mL 
of blood was taken from each patient and, after 
separation, the sera were stored in the freezer 
at -70°C. Subjects with active infection (fever 
or other evidence of infection) were excluded. 
The control subjects were healthy individuals 
with normal serum urea and creatinine. Hep­
cidin (IBL) and pro-hepcidin (Glory Science) 
were measured by the enzyme-linked immuno­
sorbent assay method. The serum ferritin was 
measured by the luminescence quantitative 
method (Monobind).
  To investigate the correlation between diffe­
rent variables and eliminate confounding va­
riables in the subjects of the study, we used 
multivariate analysis (logistic regression). For 
this purpose, variables that had a P-value <0.2 
on univariate analysis were entered into the 
multivariate analysis. For comparison of the 
mean of variables that was not normally dis­
tributed, the Mann–Whitney test was used and 
for variables that had normal distribution, the 
Student t-test was used. The chi-square test 
was used to evaluate the qualitative variables 
and the t-test was used to compare the quanti­
tative variables between the two groups. A P-
value <0.05 was considered significant. This 
study was performed with the approval of the 
Research Ethics Committee of the Golestan 
University of Medical Sciences. 
Results
  In each of the groups, 54.5% of the parti­
cipants were male (P = 0.58). 31.8% of the 
patient group and 27.3% of the control group 
had age below 50 years (P = 0.41). The mean 
pro-hepcidin level in the case and control 
groups was 186.1 ± 220.3 pg/mL and 150.87 ± 
207.7 pg/mL, respectively (P = 0.45). The 
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mean hepcidin level in the CRF patients and in 
the normal controls was 999.3 ± 996.7 ng/mL 
and 770.4 ± 815.9 ng/mL, respectively (P = 
0.25). In CRF patients, the mean pro-hepcidin 
level was 168.2 ± 226 pg/mL in males and 
207.7 ± 216.9 pg/mL in females (P = 0.54) 
and the mean hepcidin was 816.8 ± 840.6 
ng/mL in males and 1218.2 ± 1140.4 ng/mL in 
females (P = 0.77). In the control group, the 
mean pro-hepcidin was 123.6 ± 161.5 pg/mL 
in males and 182.5 ± 252 pg/mL in females (P 
= 0.84) and the mean hepcidin was702.3 ± 
757.2 ng/mL in males and 849.2 ± 893.4 
ng/mL in females (P = 0.73) (Table 1).
  The mean serum ferritin was 816.4 ± 379.4 
ng/mL in the case group and 193 ± 171.8 
ng/ml in the control group (P (0.001>. In the 
case group, no significant correlation was ob­
served between serum ferritin and hepcidin 
and pro-hepcidin levels (r = 0.6, P = 0.08). 
Also, in this group, a significant positive cor­
relation was observed between pro-hepcidin 
and hepcidin levels (r = 0.92, P <0.01). In the 
control group, no significant correlation was 
seen between serum ferritin and hepcidin (r = 
0.4, P = 0.14) and pro-hepcidin levels (r = 0.7, 
P = 0.06). Also, in this group, a significant 
correlation was seen between pro-hepcidin and 
hepcidin levels (r = 0.8, P (0.01>. The level of 
hepcidin had a direct correlation with the dura­
tion on dialysis in the case group, but it was 
not significant (r = 0.3, P = 0.06). Also, a di­
rect correlation was observed between dura­
tion on dialysis and pro-hepcidin levels (r = 
0.3, P = 0.09). On multivariate regression ana­
lysis of the variables such as age and ferritin, 
pro-hepcidin and hepcidin levels, the only va­
riable that was significantly associated with the 
risk of anemia was ferritin levels (P <0.001). 
Discussion
  This study was conducted to evaluate the 
serum levels of hepcidin in HD patients and 
normal subjects. In our study, the mean pro­
hepcidin level had no significant difference in 
the case and control groups. Tomosug et al, in 
a study in 2006, measured the hepcidin levels 
in patients with CRF and found that the 
hepcidin level was approximately two- to 
three-times higher than in the control group. In 
contrast, serum levels of β2–microglobulin, 
which is a low molecular weight protein that is 
controlled almost totally by glomerular filtra­
tion, there was a 20–30-times increase in the 
levels. Thus, glomerular filtration has little 
effect on hepcidin level that theoretically may 
explain the presence of an unknown carrier in 
the circulation for hepcidin, which can cause 
decreased renal clearance of this molecule.14 
Young et al in a study in 2009 showed that the 
pro-hepcidin level increases in dialysis pa­
tients and correlates inversely with the glo­
merular filtration rate (GFR). However, pro­
hepcidin has minimal interaction with iron or 
inflammatory parameters in dialysis patients; 
also, it seems that pro-hepcidin is an interme­
diate metabolite and without physiological 
activity and its level is not associated with the 
active production of hepcidin.15 In the study 
performed by Zaritsky et al in 2009, the serum 
ferritin level in children with CRF was higher 
than in adults with CRF.16 In our study, there 
was no significant correlation between ferritin 
and hepcidin and pro-hepcidin levels.
  In a study performed by Busbridge et al in 
patients with inflammatory bowel disease, a 
direct correlation was reported between ferritin 
and hepcidin levels.17 The mismatch of the 
results may be due to successful HD or small 
sample size. It is recommended that further 
studies should be performed with a larger sam­
ple size and the blood levels of these variables 
should be compared with the erythrocyte 
indices. In our study, no significant correlation 
was seen between duration on dialysis and 
Table 1. The mean hepcidin and pro-hepcidin levels in the two age-groups studied. 
Group Test Under 50 years Over 50 years P-value 
Case Pro-hepcidin (pg/mL) 186.2 ± 228.7 186.1 ± 220.2 0.6 
Hepcidin (ng/mL) 1021.6 ± 148.9 988.9 ± 989.7 0.57 
Control Hepcidin (ng/mL) 977.4 ± 1026.9 684.7 ± 714.6 0.6 
Pro-hepcidin (pg/mL) 215.9 ± 294.4 124 ± 158.1 0.6 
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hepcidin and pro-hepcidin levels. In a study 
performed by Li et al, the hepcidin level was 
higher in patients with renal failure and those 
on HD.11 Peters et al in their study in 2010 
from Holland found that the hepcidin level 
was higher in patients on chronic HD than in 
the control group. They also showed that the 
ferritin level in CRF and HD groups was 
higher than in the control group and found a 
significant correlation between hepcidin and 
ferritin levels. They concluded that the ferritin 
level is the only predicting factor for hepcidin 
level.12 
According to studies performed in 2008 and 
2010, it seems that the hepcidin level has no 
correlation with duration of dialysis, but the 
GFR is an important factor that shows corre­
lation with the hepcidin level.6,12 Abbasi et al 
reported that the pro-hepcidin level in CRF 
patients was higher than in the control group.18 
According to a study that was performed in 
2011, the hepcidin level did not show a corre­
lation with sex, race and age.19 In our study, 
the mean serum ferritin was significantly 
higher in the dialysis group than in the control 
group. In a study performed by Nakanishi et al 
in 2011, direct and significant correlation was 
observed between serum ferritin and hepcidin 
levels.20 
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